Our approach
Our team is passionate about applying SITESEEKER® technology to open up new druggable space and bring the next generation therapies to market. In doing so, we aim to change the face of drug discovery.
PhoreMost
PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary PROTEINi® technology, SITESEEKER systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes addressing a range of unmet diseases.
Our culture
In order to achieve this, we have an open culture that is science-driven and entrepreneurial in nature. Our people are central to achieving our aims and we recognise this through fostering career growth opportunities. Whether it is through working with our global network of collaboration partners, our inter-disciplinary project teams or doing great science, we are committed to developing our talent.
Great people with great technology can do amazing things. At PhoreMost we have built an exceptional team, making us extremely well-placed to deliver on the potential of SITESEEKER® to unlock the therapeutic potential of previously undruggable targets.
Chris Torrance, CEO